Malaria Clinical Trial
— REDHOTOfficial title:
Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys
In this study, the investigators propose to determine the value of rolling out four targeted
malaria control efforts in reducing overall malaria transmission. These targeted control
efforts include local upscaling of IRS and ITNs in hotspots of malaria transmission. In
addition, larviciding will be employed to target malaria vectors, also those that are less
susceptible to IRS and ITNs as a consequence of outdoor feeding and resting. Lastly, the
human infectious reservoir will be reduced in hotspots of malaria transmission by treating
parasite carriers and their household members with the current first-line antimalarial drug.
The impact of these targeted interventions on overall transmission intensity will be
assessed in the context of currently ongoing malaria control activities in a plausibility
study. Hotspots of malaria transmission are defined in an area of 100km2 and randomized to
receive hotspot targeted interventions and compared with their baseline and with control
clusters where the routine (untargeted) malaria control activities continue. The
interventions will be evaluated based on changes in parasite prevalence measured in
community surveys inside and outside hotspots of malaria transmission. Parasite prevalence
will be compared before and after the intervention in intervention clusters and between
intervention and control clusters.
In addition to malaria surveys in the human population, an entomological evaluation will
take place where the densities of mosquito larvae and adult mosquitoes are monitored
longitudinally.
| Status | Completed |
| Enrollment | 17506 |
| Est. completion date | November 2012 |
| Est. primary completion date | November 2012 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 6 Months and older |
| Eligibility |
Exclusion Criteria: - For LLINs, IRS and larviciding there are no exclusion criteria - Pregnant women and children < 6 months of age are excluded from FSAT |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Radboud University | Centers for Disease Control and Prevention, Division of Malaria Control, Ministry of Health, Nairobi, Kenya, International Centre of Insect Physiology and Ecology, Mbita, Kenya, Kenya Medical Research Institute, Kisumu, Kenya, London School of Hygiene & Tropical Medicine, London, UK |
Kenya,
Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012 Jan;9(1):e1001165. doi: 10.1371/journal.pmed.1001165. Epub 2012 Jan 31. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Parasite prevalence in the evaluation zone surrounding malaria hotspots | Parasite prevalence, determined by PCR, in the evaluation zone surrounding hotspots in intervention and control clusters | 3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season) | No |
| Secondary | Parasite prevalence inside malaria hotspots | Parasite prevalence, determined by PCR, inside hotspot of malaria transmission in intervention and control clusters | 3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season) | No |
| Secondary | Parasite prevalence in the evaluation zone as function of distance to the hotspot boundary | Parasite prevalence, determined by PCR, in relation to distance to the boundary of malaria hotspots in intervention and control clusters | 3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season) | No |
| Secondary | Anopheles mosquito density | Indoor and outdoor anopheles mosquito density inside and outside hotspots of malaria transmission in intervention and control clusters | determined during fortnightly trapping, starting at enrolment and continuing until up to 210 days after enrolment | No |
| Secondary | Passive case detection | Number of malaria cases reporting at health facilities, coming from intervention and control clusters | determined continuously for a period of up to 210 days after enrolment | No |
| Secondary | Safety and acceptability of interventions | Side effects of FSAT, LLINs and IRS in targeted households | at a single cross-sectional survey 15-45 days after enrolment | Yes |
| Secondary | Mosquito breeding site productivity | The presence and density of anopheles larvae in mosquito breeding sites in malaria hotspots in intervention and control clusters | determined on a weekly basis for a period of up to 210 days after enrolment | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |